Phenotype-Genotype Correlation in Wilson Disease in a Large Lebanese Family: Association of c.2299insC with Hepatic and of p. Ala1003Thr with Neurologic Phenotype

Junlar Usta1, Antonios Wehbeh2, Khaled Rida1, Omar El-Rifai1, Theresa Alicia Estiphan2, Tamar Majarian1, Kassem Barada3*

1 Department of Biochemistry and Molecular Genetics; Faculty of Medicine, American University of Beirut, Beirut, Lebanon, 2 Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon, 3 Department of Internal Medicine, American University of Beirut Medical Center, Faculty of Medicine, Beirut, Lebanon

Abstract

Genotype phenotype correlations in Wilson disease (WD) are best established in homozygous patients or in compound heterozygous patients carrying the same set of mutations. We determined the clinical phenotype of patients with WD carrying the c.2299insC mutation in Exon 8 (c.2299insC) or the p. Ala1003Thr missense substitution in Exon 13 mutations in the homozygous or compound heterozygous state. We investigated 76 members of a single large Lebanese family. Their genotypes were determined, and clinical assessments were carried out for affected subjects. We also performed a literature search retrieving the phenotypes of patients carrying the same mutations of our patients in the homozygous or compound heterozygous state. There were 7 consanguineous marriages in this family and the prevalence of WD was 8.9% and of carriers of ATP7B mutation 44.7%. WD was confirmed in 9 out of 76 subjects. All 9 had the c.2299insC mutation, 5 homozygous and 4-compound heterozygous with p. Ala1003Thr. Six of our patients had hepatic, 2 had neurologic and 1 had asymptomatic phenotype. Based on our data and a literature review, clear phenotypes were reported for 38 patients worldwide carrying the c.2299insC mutation. About 53% of those have hepatic and 29% have neurologic phenotype. Furthermore, there were 10 compound heterozygous patients carrying the p. Ala1003Thr mutation. Among those, 80% having c.2299insC as the second mutation had hepatic phenotype, and all others had neurologic phenotype. We hereby report an association between the c.2299insC mutation and hepatic phenotype and between the p. Ala1003Thr mutation and neurologic phenotype.

Introduction

Wilson disease (WD; MIM# 277900) is an autosomal recessive, copper transport disorder characterized by extensive phenotypic diversity [1,2]. Patients may present at any age with hepatic, neurologic, or mixed symptoms. Yet some may be asymptomatic [3]. WD is due to a defective ATP7B gene (OMIM*606882; Ref seq accession #: NM_000053.3); that is located on chromosome 13 (Gene map locus: 13q 14.3–921.1) that encodes a copper transporting p-type ATPase [4,5]. More than 500 mutations have been identified so far, and ongoing efforts to associate these with disease phenotypes have been inconclusive and controversial [6]. Inability to establish genotype-phenotype correlations may be attributed to the large number of mutations that occur in only few families, and to the heterogeneity of the clinical presentation of WD patients even within members of the same family. The fact that the majority of patients are compound heterozygote, having a different mutation on each allele, makes it hard to relate a phenotype with one mutant allele. Furthermore occupational exposure to copper has been shown to cause genomic alterations and DNA damage [7]. This in combination with epigenetic modulators and environmental factors may play a role in the phenotypic heterogeneity of WD patients [8]. These difficulties may be partially overcome by studying WD in homozygous patients [9].

Specific mutations in the ATP7B gene are more frequent in populations where consanguinous marriages are prevalent. In Lebanon, consanguinity has a prevalence of 35.5%, increasing the probability of homozygosity for autosomal recessive diseases [10]. We have previously reported on multiple Lebanese families with members affected with WD. We found an association between the homozygous missense mutation p. Gly691Arg (Exon-7) with early and severe hepatic disease [11]. In addition an association between liver disease and homozygous mutations in the conserved ATP hinge region (Exon-18; p. Asn1270Ser and p. Pro1273Leu) of the ATP7B gene [9] was suggested. In a recent study we reported that...
patients with homozygous missense mutations, other than p. His1009Gln, are more likely to have a hepatic phenotype, liver failure and present at a younger age [12].

In this paper, we report on the phenotype and genotype of 9 patients with WD who belong to a single large family with extensive consanguinity. Five of our patients were homozygous for c. 2299insC (Exon-8), and four were compound heterozygous for both the c. 2299insC (Exon-8) and the missense mutation p. Ala1003Thr (Exon-13). Both mutations were previously reported as disease causing mutations [8,13,14]. A literature search retrieving reported phenotypes of all patients carrying either one or both of these two mutations was performed and compared to our own. We hereby suggest that the c. 2299insC favors a hepatic phenotype while the p. Ala1003Thr favors a neurologic phenotype.

Materials and Methods

Patients/Subjects

A total of 235 individuals distributed over 6 generations in a single extended Lebanese family, the S-family, were identified. This family came to our attention after some of its members were diagnosed with WD at the American University of Beirut Medical Center (AUBMC). Seventy six subjects (S1- S76) belonging to the S-family were enrolled in the study. Whenever an index case of WD was identified, a full clinical and genetic evaluation of that patient was conducted at AUBMC, while genotypic analysis was performed on the patient as well as all his/her family members. Out of the 76 subjects, 9 were found to have WD. Patient evaluation consisted of a full history, complete physical and neurological examination, ophthalmologic slit-lamp examination for Kayser-Fleischer (KF) rings, abdominal ultrasound, and standard biochemical tests including liver function tests, serum ceruloplasmin, serum copper and 24 hr urinary copper levels. Ceruloplasmin level was determined using immuno nephelometric method (BN ProSpec analyzer system, from Siemens. Serum and urine copper levels were performed in a reference Laboratory (CERBA, France) as service, using Atomic absorption and ICP-MS, respectively. Five patients had brain MRI and two had EEG done as part of their evaluation.

DNA screening for exons bearing mutations or single nucleotide polymorphisms (SNPs) was performed in all recruited subjects. Cases were labeled as hepatic, neurologic, or asymptomatic following Ferencí’s classification [15].

Detailed information was obtained from available family members in order to construct an accurate pedigree representing the 235 individuals of the S-family. Twelve members of the S-family died of WD according to information provided by their family members. Data pertaining to the clinical and genetic profiles of these deceased patients could not be obtained.

Ethics Statement

Written informed consent for participation in this study was obtained from all subjects or their guardians. The study protocol #: BioCh. JU.01 was approved by the International Review Board and the Research Committee at the American University of Beirut-Medical Center.

Mutation Analysis

Materials and Reagents. Various reagents used in this study were purchased from the following suppliers: IQ supermix, and Agarose from Bio-Rad; DNA purification Kit using Nucleospin Extract II columns from Machery Nagel, Germany (Cat no. 740609-50); T4 Kinase Polynucleotide from Invitrogen; γ-32P- ATP from Amersham (5000 Ci/mmole); SSDNA from Sigma Aldrich cat# D7656; Sephadex columns from GE Healthcare (Microspin G-25 column illustra 27-5325-01); and T4-Kinase from Invitrogen, Life Technology.

DNA concentration was quantified using the Gene Quant Spectrophotometer. PCR was performed using My Cycler Thermal Cycler from Bio-Rad; Membrane hybridization and crosslinking were carried out using ProBlot 12 Hybridization Oven Labnet, (31 Mayfield Avenue Edison, N.J., 08837 USA), and Spectrolinker UV Crosslinkers from Kraneker Scientific, Inc. PO Box 1849 Albany, NY 12201-1849), respectively. Sequencing of purified DNA was carried out at the University of Saint Joseph, Department of Molecular Biology and Genetics using the Avant Genetic Analyzer (ABI 3130) machine. The sequencing reaction and subsequent purification steps were as described before [9].

Genotypic Analysis. Blood samples were collected in EDTA containing tubes, from 9 WD patients of the S-family and related members for DNA isolation. Blood samples were collected in EDTA containing tubes from 9 WD patients of the S-family and related members for DNA isolation. In brief Red Cell Lysis Buffer (RCLB composed of: 7.7 g ammonium chloride and 0.1 g potassium bicarbonate were dissolved in 11 water) was added to blood sample (2v/1v), incubated at 37°C for 12 min, and centrifuged (4000rpm, 2 min). The resultant pellet was re-suspended in RCLB (2 ml) followed by the consecutive addition of: white cell lysis buffer (1.8 ml, WCLB composed of: 1.2 g TRIS, 1.68 g EDTA, 23.4 g sodium chloride dissolved in 11 water), SDS (24 µl of 10%) and proteinase- K (18 µl of 20 mg/ml). The suspension was incubated for 2 hrs at 55°C and proteins were salted out by adding 600 µl of 5 mM NaCl, followed by centrifugation at 4000 rpm for 15 min. The supernatant was transferred to a clean tube where an equal volume of ethanol (99%) was added to precipitate DNA. The flocculent DNA was transferred into 1.5 ml eppendorf tube, washed with 70% ethanol (200 µl), and centrifuged at maximum speed for 1min. The supernatant was then discarded. The pellet was allowed to air-dry and was then finally suspended in 200 µl TE buffer. DNA concentration was determined using Gene Quant Spectrophotometer at λ= 260 nm, and samples were stored at −20°C.

Polymerase Chain Reaction (PCR). Amplification of Exons 2-21 of WD gene were carried on all samples using My Cycler, (BIO-RAD), Primers flanking the exons' boundaries were designed (will be provided upon request) according to Petrukhin et al [16] with minor changes using primer 3 software (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). The PCR reaction mixture contained in a final volume of 50 µl: 25 µl IQ supermix (Biorad), 22 µl H2O, 1 µl of each of the primers (forward, reverse) each at a concentration of 3.4 pmoles/µl, and 1 µl DNA (250 ng). Two PCR programs were used in amplifying the exons:

Program-1 involved activation of Taq polymerase (94°C, 2 min), 38 cycles of denaturation (94°C, 30 sec), annealing (59°C, 30 sec), Extension (72°C, 40 sec) and a final extension (72°C, 7 min) followed by hold step. This program was used to amplify exons: 2, 4–10, 15 and 17.

Program-2 was similar to program 1, except for the annealing temperature it was 61°C. This program was used to amplify exons: 3, 11–14, 16, and 18–21. Amplified PCR products were then separated on 2% agarose gel, compared to DNA ladder of Molecular weight standards. DNA band corresponding to appropriate size were cut and purified using gel-extraction kits, Nucleospin Extract II columns (Machery Nagel), following Manufacturer’s instructions. Sequencing of amplified exons was performed on WD patients as detailed in [9,12], compared to published normal sequences in the various databases either Blast
Genotypic screening of all other subjects was performed using DOT blot analysis following standard protocols [17]. Random selection of the amplified ATP7B exons: 0,10,12,13, and 16 from subjects (including WD patients) screened by Dot Blot, were sequenced to verify the Dot blot results.

Dot Blot Analysis

a. Labeling of probes. Normal and mutant probes were designed to include nucleotide base changes (mutations, SNPs) identified in patients. Probes (Table S1) were labeled using gamma 32P-ATP as per instruction of the T4 kinase polynucleotide supplier. The labeled 32P-probes were then denatured and centrifuged onto sephadex G-25 columns for 1min at 2400 rpm, where samples of the eluted probe were counted using liquid scintillator.

b. Membrane Preparation and Hybridization. Amplified PCR products were diluted to 0.4 ng/μl with 0.4 M NaOH – 10 mM EDTA, denatured by heating (10 min at 100°C), cooled & loaded on positively charged nitrocellulose membrane using Bio Blot machine (Bio-Rad), and washed consecutively with NaOH (100 μl, 0.4 M) followed by 2 X SSC (prepared as described in Current Protocols in Molecular Biology [17]). Briefly, the membrane was allowed to dry at room temperature and was then cross linked for 30 seconds using UV cross linker. Following pre-hybridization of membranes with aqueous prehybridization (APH) solution and denatured Salmon Sperm DNA (SSDNA) for 3hrs at 60°C, cross linked membranes were hybridized for 3–4 hours with labeled probes (106 cpm/300 ng) (Exons: 8,10,12,13, 16 at 45°C, 42°C, 30°C, 53°C, 43°C respectively), and were then washed at different stringencies (Table 1), dried, wrapped and exposed onto X-Ray films for 24–72 hours.

Literature Review

We conducted a comprehensive literature search of PubMed and Medline at National Center For Biotechnology Information (http://www.ncbi.nlm.nih.gov/Blast) or Blat at University of California Santa Cruz, Genome Bioinformatic site (http://www.genome.ucsc.edu/cgi-bin/lgBlat).

Genotypic screening of all other subjects was performed using DOT blot analysis following standard protocols [17]. Random selection of the amplified ATP7B exons: 0,10,12,13, and 16 from subjects (including WD patients) screened by Dot Blot, were sequenced to verify the Dot blot results.

Dot Blot Analysis

a. Labeling of probes. Normal and mutant probes were designed to include nucleotide base changes (mutations, SNPs) identified in patients. Probes (Table S1) were labeled using gamma 32P-ATP as per instruction of the T4 kinase polynucleotide supplier. The labeled 32P-probes were then denatured and centrifuged onto sephadex G-25 columns for 1min at 2400 rpm, where samples of the eluted probe were counted using liquid scintillator.

b. Membrane Preparation and Hybridization. Amplified PCR products were diluted to 0.4 ng/μl with 0.4 M NaOH – 10 mM EDTA, denatured by heating (10 min at 100°C), cooled & loaded on positively charged nitrocellulose membrane using Bio Blot machine (Bio-Rad), and washed consecutively with NaOH (100 μl, 0.4 M) followed by 2 X SSC (prepared as described in Current Protocols in Molecular Biology [17]). Briefly, the membrane was allowed to dry at room temperature and was then cross linked for 30 seconds using UV cross linker. Following pre-hybridization of membranes with aqueous prehybridization (APH) solution and denatured Salmon Sperm DNA (SSDNA) for 3hrs at 60°C, cross linked membranes were hybridized for 3–4 hours with labeled probes (106 cpm/300 ng) (Exons: 8,10,12,13, 16 at 45°C, 42°C, 30°C, 53°C, 43°C respectively), and were then washed at different stringencies (Table 1), dried, wrapped and exposed onto X-Ray films for 24–72 hours.

Literature Review

We conducted a comprehensive literature search of PubMed and Medline at National Center For Biotechnology Information (http://www.ncbi.nlm.nih.gov/Blast) or Blat at University of California Santa Cruz, Genome Bioinformatic site (http://www.genome.ucsc.edu/cgi-bin/lgBlat).

Table 1. Summary of the washing stringency conditions optimized for the different normal and mutant probes.

| Hybridization | Washings | Volume ml/Time min/Temperature °C |
|---------------|----------|---------------------------------|
| 15ml APH + labeled probes for 3–4hours at specific annealing temperature | | Exon8 | Exon10 | Exon12 | Exon13 | Exon16 |
| 2XSSC-0.1%SDS | 15/10/25 | 15/10/25 | 20/30/25 | 15/10/25 | 25/25/25 |
| 2XSSC-0.1%SDS | 15/10/25 | 15/10/25 | 20/30/25 | 15/10/25 | 25/25/25 |
| 0.2XSSC-0.1%SDS | 15/20/25 | 15/15/25 | 20/25/34 | 20/25/25 | 20/25/25 |
| 0.2XSSC-0.1%SDS | 15/20/57 | - | - | 20/30/61 | - |
| 0.1XSSC-0.1%SDS | - | 15/20/50 | - | - | 20/30/49 |

Radioactive 32P labeled normal and mutant probes of Exons: 8, 10, 12, 13, &16 were hybridized with amplified denatured DNA loaded on positively charged membrane. Membranes were then washed under different stringency conditions with SSC- SDS. The abbreviation SSC-SDS stands for: Sodium chloride: Tri-Sodium Citrate (3 M: 0.3 M, pH 7) - Sodium Dodecyl Sulfate used at the indicated volume in ml, time in minutes and temperature °C.

doi:10.1371/journal.pone.0109727.0001

Results

Clinical features

A pedigree of the S-family is presented Fig.1 showing the 235 members, and including all affected individuals and their immediate families. There were 7 consanguinous marriages in this family. Out of the 76 individuals enrolled in this study, 9 (11.8%) were diagnosed with WD (5 females & 4 males), and those are coded as: (S1, S2, S3, S4, S7, S8, S31, S41, and S59). Seven of the 9 patients belonged to 3 nuclear families, these are: (S1, S31, S59), (S7, S8) and (S3, S4). Six patients had a hepatic phenotype, two had neurologic phenotype, and one was completely asymptomatic and diagnosed by screening. Twelve out of the remaining 159 members had passed away because of WD according to their family members. Their clinical characteristics and genotype could not be determined. The prevalence of WD in the S-family, taking into account both the alive and deceased individuals, is 8.9% (21/235).

Eight patients had decreased serum ceruloplasmin level, while patient S41 had a normal level. The 24-hour urinary copper level was markedly elevated in 8 patients (average of 695.1 μg/24 hr) but was normal in one patient (S59) who was diagnosed by screening at the age of 1 year. KF rings were present in 6 affected subjects.

The clinical profiles of affected individuals are summarized in Table 2. The average age at diagnosis was 11.2 years, while the mean age of patients with hepatic and neurologic manifestation were 9.7 and 14 years, respectively.

Among the 6 patients with hepatic disease, 3 patients (S3, S4, and S7) had liver cirrhosis with portal hypertension. Patient (S3) presented with lethargy and gingival bleeding and subsequent endoscopy showed grade-3 esophageal varices. CT scan of the abdomen showed marked splenomegaly and a nodular liver consistent with cirrhosis. Patient (S4) had coarse hepatomegaly, splenomegaly, as well as a dilated portal vein by abdominal ultrasound, in addition to a prolonged INR ranging between 1.2–1.4, as well as arthropathy. Her brain MRI showed mild increase in signal intensity in the frontal lobes while her EEG was normal. Patient (S7) presented with jaundice, increased abdominal girth, pitting edema, bleeding tendency along with generalized weakness.
She had no neurologic symptoms and her neurologic exam was normal. Her brain MRI showed bilateral ill-defined symmetrical areas of increased signal intensity involving Globus Pallidus and posterior limbs of internal capsule. In addition her abdominal ultrasound revealed changes of chronic liver disease as well as portal hypertension.

Patients (S1, S3) were found to have hepatomegaly by abdominal ultrasound and asymptomatic transaminitis upon diagnosis, with their alanine aminotransferase levels being elevated to 118 U/L and 105 U/L respectively. S1 had a normal Brain MRI and an EEG showing rare sharp waves in the right parietal area. Patient (S3) had hepatic involvement confirmed by ultrasoundography showing fatty liver.

Two patients (S2, S4) presented with pure neurologic manifestations of WD at 12 and 16 years of age, respectively. The first presented with tremors, ataxia, slurred speech, in addition to arthropathy, while the second developed tremors, rigidity, and abnormal gait. Brain MRI of the former showed increased signal intensity in the basal ganglia and brain stem with involvement of brachium pontis bilaterally.

One patient (S8) who was asymptomatic had normal liver function tests, abdominal imaging, and brain MRI. The remaining 67 enrolled subjects were unaffected.

Mutation Analysis

The spectrum of mutations in the *ATP7B* gene of the S family was determined by sequencing exons 2–21 in WD patients (9/76) of the S family. DNA mutation numbering is based on cDNA. Genotypic findings of disease causing mutations are listed in Table 2. Five patients (S1, S2, S31, S41, and S59) were homozygous for a frame shift mutation (c. 2299insC/c. 2299insC, Exon-8/8). Four patients, (S3, S4, S7 and S8) were compound heterozygous for the frame shift in exon-8, and missense mutation (c.3007G>A substitution) in exon-13: (c. 2299insC/p. Ala1003Thr). In addition all affected patients were simultaneously homozygous for 2 SNPs in Exon-16 (p. Val1140Ala) and Exon-12 (p. Arg 952 Lys). A SNP in Exon-10 (p. Lys332Arg) was also identified in the homozygous state in patients S1, S2, S31, S41, and S59; in the heterozygous state in S7 and S8; while it was normal in S3 and S4. Patients had normal sequences in all remaining exons: 2–7, 9, 11, 14, 15, 17, 18, 19, 20, and 21. Further screening of related family members using dot blot (Fig. 2) identified a high rate of mutant allele carriers (44.7%) distributed as: 23/76 for the c. 2299insC (30.2%) and 11/76 for p. Ala1003Thr (14.5%). Random selection of the amplified ATP7B exons: 8, 10, 12, 13, and 16 from subjects screened by Dot Blot and including WD patients, were sequenced. Out of the 76 subjects a total of: 29 subjects for Exon-8; 19 subjects for Exon-10; 14 subjects for Exon-12; 23 subjects for Exon-13, and 17 subjects for Exon-16 were sequenced confirming our Dot Blot findings.

Literature review findings

A total of 17 articles were included based on the following criteria: 1) the patient carries one of the aforementioned mutations in the homozygous or heterozygous state, or carries both of these mutations, and 2) the corresponding phenotypic presentation is stated as hepatic, neurologic, mixed or asymptomatic. Tables 3 and 4 present the number, age and nationality of patients that meet our inclusion criteria.

A total of 14 patients, including 5 of ours (this study), were homozygous for the c. 2299insC mutation (Table 3). The most common presentation was hepatic identified in 57%, while each of neurologic and asymptomatic equally presented at 21.4%. The majority of asymptomatic patients had transaminitis [18,19].

Twenty four compound heterozygous patients, carrying the c. 2299insC/allele, were identified worldwide with 12 hepatic (50%), 8 neurologic (33.3%), 3 mixed (12.5%) phenotypes and 1 asymptomatic (4%).

There were 11 patients carrying the p. Ala1003Thr mutation (c.3007G>A substitution), one of whom was homozygous and presented with hepatic phenotype at a young age (Table 4). Ten patients were compound heterozygous carrying the p. Ala1003Thr mutation on one allele. Patients with c. 2299insC on the second allele had a predominant hepatic presentation (4/5) with mean age of 13.5 yrs, whereas all patients (5/5) with non c. 2299insC on the second allele had neurologic presentation with a mean age of 22 years. One asymptomatic patient with the (c. 2299insC/p. Ala1003Thr) was diagnosed by screening at 15 years of age.

Discussion

We report in this paper the genotype-phenotype correlations in a very large single family with extensive consanguinity and a high prevalence of WD. The main finding of our study and of the literature review is an association between the c. 2299insC mutation in the homozygous and the compound heterozygous
### Table 2. Clinical, biochemical and genetic profile of WD patients in the S family.

|                  | S1         | S2         | S3         | S4         | S7         | S8         | S31        | S41        | S59        |
|------------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|
| Year of birth    | 1993       | 1973       | 1981       | 1983       | 1993       | 1989       | 1997       | 1980       | 2007       |
| Age (y) of symptoms onset | -          | 12         | 15         | 13         | 12         | -          | 16         | -          | -          |
| Age (y) at diagnosis | 5 by screening<sup>a</sup> | 12         | 16         | 14         | 12         | 15 by screening<sup>a</sup> | 10 by screening<sup>a</sup> | 16         | 1 by screening<sup>a</sup> |
| Clinical findings |            |            |            |            |            |            |            |            |            |
| GI manifestations | Asymptomatic transaminitis, hepatomegaly | Absent<sup>b</sup> | Cirrhosis | Cirrhosis | Cirrhosis | Absent | Asymptomatic transaminitis, hepatomegaly | Absent | Asymptomatic fatty liver |
| Neurological     | Absent     | Slurred speech, ataxia, tremors | Absent | Absent | Absent | Absent | Absent | Absent | Absent | Absent | Absent | Absent | Absent | Absent | Absent | Absent |
| Other            | Absent     | Arthralgia | Absent     | Absent     | Absent     | Absent     | Absent     | Absent     | Absent     | Absent     | Absent |
| MRI of Brain     | Normal     | Increased signal intensity in the basal ganglia & brain stem | — | Mild increase in signal intensity in the frontal lobes | Increase in signal intensity involving globus pallidus | Normal | — | — | — | — |
| Kayser-Fleischer ring | Absent     | Present    | Present    | Present    | Present    | Present    | Present    | Absent     | Present    | Present    |
| Laboratory findings |             |            |            |            |            |            |            |            |            |            |            |
| Serum ceruloplasmin g/L | <0.04 | 0.072 | 0.096 | 0.096 | 0.17 | 0.12 | 0.03 | 0.423<sup>c</sup> | <0.019 |
| Serum Cu(µg/dL)   | 15         | 23         | 58         | 75         | 45         | 41         | 9          | 133.35     | <5         |
| 24h urine Cu (µg) | 99         | 512        | 775        | 590        | 645        | 487        | 152.8      | 230<sup>c</sup> | 10         |
| ALT, AST (IU/mL)  | 289, 167   | 17, 13     | 30, 41     | 30, 35     | 29, 45     | 45, 41     | 105, 51    | 3, 20      | 44, 37     |
| Bilirubin T/D (mg/dl) | 0.3/0.1 | 0.4/0.2 | 0.5/0.2 | 0.4/0.1 | 0.7/0.3 | 0.7/0.2 | 0.2/0.1 | 1/0.4 | 0.3/0.1 |
| Albumin (g/L)     | 50         | 43         | 35         | 43         | 37         | 40         | 45         | 45         | 47         |
| INR               | 1.3        | 1.3        | 1.3        | 1.3        | 1.2        | 1.1        | —          | 1          | 1.1        |
| ATP7B Mutations*  | 2299insC/2299insC | 2299insC/2299insC | 2299insC/p. Ala1003Thr | 2299insC/p. Ala1003Thr | 2299insC/p. Ala1003Thr | 2299insC/p. Ala1003Thr | 2299insC/2299insC | 2299insC/2299insC | 2299insC/2299insC |

<sup>a</sup>Screening refers to genetic screening of the ATP7B gene exons' by PCR followed by sequencing; <sup>b</sup>Few years later developed liver cirrhosis and portal hypertension; <sup>c</sup>Normal ranges of: Serum ceruloplasmin: 0.15–0.60 g/L; Serum Cu: 70–150 µg/dL; 24h urine Cu: 15–50 µg/24h; Bilirubin T/D: 0.2–1.2/0–0.5; Level determined after 7 years of treatment; <sup>d</sup>Urinary Cu level while S41 was on penicillamine; <sup>e</sup>c.2298_2299insC is referred to as 2299insC. DNA Mutation numbering is based on cDNA numbering where nucleotide +1 as the A of the ATG translation initiation codon, in the reference sequence # NM_000053 with the initiation codon as codon +1.

doi:10.1371/journal.pone.0109727.t002
state and hepatic phenotype. On the other hand, there is an association with the mutation p. Ala1003Thr in the compound heterozygous state with a neurologic phenotype. Based on the most recent EASL practice guidelines, all patients in our study have definite Wilson disease [20].

More than 500 mutations have been described in WD, and missense ones are the most common. The majority of those mutations are rare and most patients are compound heterozygote. Hence, establishment of convincing genotype correlations has been difficult and results inconclusive [8,21–25]. In addition, other epigenetic and environmental factors play a role in disease presentation. Thus, conducting large consanguineous family studies in homogenous populations would facilitate establishment of genotype phenotype correlations as members of those families are more likely to share the same genetic and environmental factors and to be homozygous [9,26].

Six of our patients had liver disease, and three of those had full blown cirrhosis and portal hypertension. No liver biopsy was performed, but the diagnosis of liver cirrhosis was firmly established based on clinical, laboratory and imaging grounds as suggested elsewhere [27,28]. All six patients had the c. 2299insC mutation in the homozygous or compound heterozygous state, and 3 of them were females. However, two male patients that were homozygous for the c. 2299insC mutation had neurologic manifestations of Wilson disease, and one of them developed cirrhosis and portal hypertension years later. No liver biopsy was done on either.

As seen in table 3, there were 38 patients carrying the c. 2299insC mutation in the homozygous or compound heterozygous state worldwide. The frequencies of the hepatic, neurologic, mixed and asymptomatic phenotype was 53%, 29%, 11% and 8%, respectively. Four of the patients who had neurologic phenotype were compound heterozygous for p. His1069Gln which is known to be associated with neurologic phenotype [29]. Conversely, there were 10 compound heterozygous patients carrying the p. Ala1003Thr mutation (Table 4). For those carrying the c. 2299insC as the second mutation, hepatic phenotype was predominant, while for all others (5 out of 5), neurologic phenotype was predominant. Thus, an important question arises.

![Figure 2. Dot blot image.](image-url)
### Table 3. Phenotypes of patients homozygous and/or heterozygous for the c. 2299insC reported in the literature.

| Genotype                  | Exons | No. of patients (age years) | Phenotype | Nationality | References                           |
|---------------------------|-------|-----------------------------|-----------|-------------|--------------------------------------|
| c.2299insC/c.2299insC<sup>a</sup> | 8/8   | 1 (7)                        | Hepatic   | Greek       | Panagiotakaki et al. [34]           |
|                           |       | 2 (NA)                      | Hepatic   | Egyptian    | Abdelghaffar et al. [35]            |
|                           |       | 1 (8)                       | Hepatic   | Cypriot     | Butler et al. [36]                  |
|                           |       | 1 (6)                       | Hepatic   | Iranian     | Dastsooz et al. [37]                |
|                           |       | 1 (10)                      | Neurologic| Chinese     | Gu et al. [38]                      |
|                           |       | 2 (1.3)                     | Asymptomatic<sup>b</sup> | Italian | Nicastro et al. [18]               |
|                           |       | 1 (NA)                      | Asymptomatic<sup>b</sup> | Egyptian | Abdel Ghaffar et al. [19]          |
|                           |       | 2 (7.5)                     | Hepatic<sup>c</sup> | Lebanese | Our study                           |
|                           |       | 1 (1)                       | Hepatic<sup>d</sup> | Lebanese | Our study                           |
|                           |       | 2 (14)                      | Neurologic| Lebanese | Our study                           |
| p.Arg616Gln/c.2299insC   | 5/8   | 1 (34)                      | Hepatic   | Yugoslavian | Loudianos et al. [39]       |
|                           |       | 1 (22)                      | Neurologic| Bulgarian | Mihaylova et al. [40]            |
|                           |       | 1 (21)                      | Mixed     | Bulgarian | Mihaylova et al. [40]            |
| p.Met645Arg/c.2299insC   | 6/8   | 1 (10)                      | Hepatic   | Spanish     | Margaret et al. [23]              |
| c.2299insC/p.Arg816Ser    | 8/9   | 1 (26)                      | Neurologic| Austrian   | Hofer et al. [41]                  |
| c.2299insC/p.Val949Gly    | 8/12  | 1 (26)                      | Neurologic| Brazilian | Deguti et al. [42]                 |
| c.2299insC/p.Ala1003Thr   | 8/13  | 1 (15)                      | Hepatic   | Yugoslavian | Loudianos et al. [39]       |
|                           |       | 3 (14)                      | Neurologic| Yugoslavian | Loudianos et al. [39]       |
|                           |       | 1 (15)                      | Asymptomatic| Lebanese | Our study                           |
| c.2299insC/p.His1069Gln  | 8/14  | 4 (23.75)                  | Neurologic| Yugoslavian | Loudianos et al. [39]       |
|                           |       | 1 (10)                      | Hepatic   | Turkish     | Simsek Papur et al. [43]          |
| c.2299insC/3402delC      | 8/15  | 1 (33)                      | Neurologic| Yugoslavian | Loudianos et al. [39]       |
|                           |       | 1 (9)                       | Hepatic   | Brazilian   | Deguti et al. [42]                 |
| c.2299insC/p.Leu1255Ile  | 8/18  | 1 (10)                      | Hepatic   | Korean      | Yoo [2]                            |
| c.2299insC/NA<sup>e</sup>  | 8/NA  | 2 (21)                      | Mixed     | Thai        | Keandaungjuntr et al. [44]        |
|                           |       | 1 (NA)                      | Hepatic   | Egyptian    | Abdelghaffar et al. [35]          |
|                           |       | 1 (19)                      | Hepatic   | Yugoslavian | Loudianos et al. [39]       |
|                           |       | 1 (10)                      | Hepatic   | Brazilian   | Deguti et al. [42]                 |

<sup>a</sup> The identified c.2298–2299insC is referred to as c.2299insC.<br>
<sup>b</sup> The majority of asymptomatic patients in this study had transaminitis or hepatomegaly.<br>
<sup>c</sup> Asymptomatic transaminitis.<br>
<sup>d</sup> Asymptomatic fatty liver.<br>
<sup>e</sup> Unidentified or not reported.

doi:10.1371/journal.pone.0109727.t003

### Table 4. Phenotypes of patients homozygous and/or heterozygous for the p. Ala1003Thr missense mutation reported in the literature.

| Genotype                  | Exons | No. of patients (age years) | Phenotype | Nationality | References                           |
|---------------------------|-------|-----------------------------|-----------|-------------|--------------------------------------|
| p.Ala1003Thr/p.Ala1003Thr | 13/13 | 1 (<8)                      | Hepatic   | Indian      | Kumar et al. [13]                   |
| c.2299insC/p. Ala1003Thr | 8/13  | 1 (15)                      | Hepatic   | Yugoslavian | Loudianos et al. [39]               |
|                           |       | 3 (14)                      | Hepatic   | Lebanese    | Our study                           |
|                           |       | 1 (15)                      | Asymptomatic| Lebanese | Our study                           |
| p.Ala1003Thr/p.His1069Gln | 13/14 | 1 (23)                      | Neurologic| Yugoslavian | Loudianos et al. [39]               |
|                           |       | 1 (26)                      | Neurologic| Danish      | Moller et al. [30]                  |
| p.Ala1003Thr/p.Val1036le  | 13/14 | 1 (25)                      | Neurologic| Turkish     | Simsek Papur et al. [43]            |
| p.Ala1003Thr/NA<sup>f</sup> | 13/NA | 1 (16)                      | Neurologic| Yugoslavian | Loudianos et al. [39]               |
|                           |       | 1 (20)                      | Neurologic| Greek       | Butler et al. [36]                  |

do:10.1371/journal.pone.0109727.t004
in compound heterozygous patients: which mutation dictates the phenotype of the patient? In view of the small number of patients and large number of mutations, this question may be difficult to answer. A suggestion by Möller LB et al [30] was made that the milder mutation dictates the age of onset and possibly the phenotype. She considered both c. 2299insC and p. His1069Gln to be severe mutations based on earlier onset of symptoms. In our study, the mean age of patients carrying the c. 2299insC mutation is 14.4 years and of those carrying the p. Ala1003Thr mutation is 17 years. Based on that, both mutations would be considered "severe". However, extensive heterogeneity exists in age of onset as shown in Tables 3 and 4.

In an ongoing study on genotype-phenotype correlations in Caucasian patients, preliminary results suggest that hepatic phenotype is present in 69% of patients who are compound heterozygous c.2299 ins/C/p. His1069Gln [8]. This is consistent with our suggestion that c. 2299insC is associated with hepatic phenotype, even when it is combined with another mutation that is associated with neurologic phenotype.

What then could explain the severe hepatic phenotype of a patient who is homozygous for p. Ala1003Thr as reported by Kumar et al [13]? We had reported before a strong association between hepatic phenotype, hepatic failure and homozygosity for missense mutations other than p. His1069Gln [12]. Thus, it looks like there are multiple genetic determinants of phenotype in WD, including homozygosity, the type of mutation and its severity, the weight of individual mutations in those who are compound heterozygote, as well as other known and unknown genetic and epigenetic factors.

Establishing genotype-phenotype correlations is clearly important for appropriate patient management, for initiation of early therapy in asymptomatic patients to prevent certain complications, and for monitoring the efficacy of treatment. Furthermore, it enhances understanding of the molecular pathogenesis of the disease. However, it is still fraught with extensive difficulties. In addition to the complex genetic factors, the extensive phenotypic heterogeneity of WD, and the small number of patients, other factors seem to be important in determining phenotype in WD. These include sex, ethnicity, environmental and dietary factors as well as percentage residual activity of the translated protein. Furthermore, younger age of onset of symptoms may contribute to the phenotype as well.

In the absence of a purified protein, our current understanding of how mutations and SNPs affect protein function, and therefore phenotype, remains speculative. It is plausible to assume that derangement in protein function varies with nature and position of mutation. Discordance in monozygotic twins suggests that environmental, dietary, and epigenetic factors including sex, ethnicity, environmental and dietary factors as well as percentage residual activity of the translated protein. Furthermore, younger age of onset of symptoms may contribute to the phenotype as well.

In conclusion, phenotype-genotype correlations in WD patients remain a challenge as long as diagnosis at the asymptomatic stage is not possible and functional assay of purified normal and mutant protein is still unavailable.

**Supporting Information**

**Table S1 Normal (N) and mutant (M) nucleotide probes and SNPs identified in the S- Family in Exons: 8, 10, 12, 13, and 16.**

**Acknowledgments**

The authors are thankful to all patients who accepted to participate in this study.

**Author Contributions**

Contributed reagents/materials/analysis tools: O ER: pedigree and consent forms, figures. Conceived and designed the experiments: JU KB. Performed the experiments: KR OER. Analyzed the data: JU KB TM TAE. Wrote the paper: JU KB TM TAE.
15. Ferenci P, Caca K, Loudianos G, Mieli-Vergani G, Tanner S, et al. (2003) Diagnosis and phenotypic classification of Wilson disease. Liver Int 23: 139–142.
16. Petrukhin K, Lutsenko S, Chernov I, Ross BM, Kaplan JH, et al. (1994) Characterization of the Wilson disease gene encoding a P-type copper transporting ATPase: genomic organization, structure/function predictions. Hum Mol Genet 3: 1647–1656.
17. Ausubel FM (1988) Current protocols in molecular biology. New York: Published by Greene Pub Associates and Wiley-Interscience. J. Wiley.
18. Nicastro E, Loudianos G, Zancon L, D’Antiga L, Maggioni G, et al. (2009) Genotype-phenotype correlation in Italian children with Wilson’s disease. J Hepatol 50: 553–561.
19. Abdel Ghaffar TY, Elsayed SM, Elsobky E, Bochow B, Buttner J, et al. (2008) Phenotypic and genetic characterization of a cohort of pediatric Wilson disease patients. BMC Pediatr 11: 56.
20. Ferenci P, Galkowska A, Streureml W, Houwen R, Rosenberg W, et al. (2012) EASL Clinical Practice Guidelines: Wilson’s disease. J Hepatol 56: 671–685.
21. Curris D, Durie K, Balac P, Sheard D, Goodve A, et al. (1999) A study of Wilson disease mutations in Britain. Hum Mutat 14: 304–311.
22. Kalinsky H, Funes A, Zeldin A, Pel-Or Y, Korostishevsky M, et al. (1998) Novel ATP7B mutations causing Wilson disease in several Israeli ethnic groups. Hum Mutat 13: 145–151.
23. Margerit E, Bach V, Gomez D, Bruguera M, Jara P, et al. (2005) Mutation analysis of Wilson disease in the Spanish population – identification of a prevalent substitution and eight novel mutations in the ATP7B gene. Clin Genet 68: 61–68.
24. Shah AB, Chernov I, Zhang HT, Ross BM, Das K, et al. (1997) Identification and analysis of mutations in the Wilson disease gene (ATP7B): population frequencies, genotype-phenotype correlation, and functional analyses. Am J Hum Genet 61: 317–328.
25. Kegley KM, Sellers MA, Ferber MJ, Johnson MW, Jocleow DW, et al. (2010) Fulminant Wilson’s disease requiring liver transplantation in one monozygotic twin despite identical genetic mutation. Am J Transplant 10: 1325–1329.
26. Thomas GR, Forbes JR, Roberts EA, Walsh JM, Cox DW (1995) The Wilson disease gene: spectrum of mutations and their consequences. Nat Genet 9: 210–217.
27. Obrador BD, Prades MG, Gomez MV, Domingo JP, Cueto RB, et al. (2006) A predictive index for the diagnosis of cirrhosis in hepatitis C based on clinical, laboratory, and ultrasound findings. Eur J Gastroenterol Hepatol 18: 57–62.
28. Pinzani M, Rombouts K, Colagrande S (2005) Fibrosis in chronic liver diseases: diagnosis and management. J Hepatol 42 Suppl: S22–36.
29. Stapelbroek JM, Bollen CW, van Amstel JR, van Erpencm KJ, van Hattum J, et al. (2004) The H1065Q mutation in ATP7B is associated with late and neurologic presentation in Wilson disease: results of a meta-analysis. J Hepatol 41: 758–763.
30. Moller LR, Horn N, Jeppesen TD, Vissing J, Wiibrand F, et al. (2011) Clinical presentation and mutations in Danish patients with Wilson disease. Eur J Hum Genet 19: 935–941.
31. Huffman DL, O’Halloran TV (2000) Function, structure, and mechanism of intracellular copper trafficking proteins. Annu Rev Biochem 70: 677–701.
32. Wilson AM, Schlade-Bartusia K, Tison JL, Macintyre G, Cox DW (2009) A minigene approach for analysis of ATP7B splice variants in patients with Wilson disease. Biochimie 91: 1342–1345.
33. Won L, Tsai CH, Hsu CM, Huang CC, Yang CC, et al. (2010) Mutation analysis and characterization of alternative splice variants of the Wilson disease gene ATP7B. Hepatology 52: 1662–1670.
34. Panagiotakaki E, Tsietz M, Maneski N, Loudianos G, Papathodorou A, et al. (2004) Genotype-phenotype correlations for a wide spectrum of mutations in the Wilson disease gene (ATP7B). Am J Med Genet A 131: 168–173.
35. Abdelghaffar TY, Elsayed SM, Elsobky E, Bochow B, Buttner J, et al. (2008) Mutational analysis of ATP7B gene in Egyptian children with Wilson disease: 12 novel mutations. J Hum Genet 53: 681–687.
36. Butler P, McIntyre N, Mistry PK (2003) Molecular diagnosis of Wilson disease. Mol Genet Metab 72: 223–230.
37. Dustoor H, Delhghani SM, Imazieh MH, Haghight M, Moemi M, et al. (2013) A new ATP7B gene mutation with severe condition in two unrelated Iranian families with Wilson disease. Gene 514: 48–53.
38. Gu YH, Kodama H, Du SL, Gu QJ, Sun HJ, et al. (2003) Mutation spectrum and polymorphisms in ATP7B identified on direct sequencing of all exons in Chinese Han and Hui ethnic patients with Wilson’s disease. Clin Genet 64: 479–484.
39. Loudianos G, Kostic V, Solinas P, Lovicu M, Dessi V, et al. (2003) Characterization of the molecular defect in the ATP7B gene in Wilson disease patients from Yugoslavia. Genet Test 7: 107–112.
40. Mihaylova V, Todorov T, Jelev H, Kotsev I, Angelova L, et al. (2012) Neurological symptoms, genotype-phenotype correlations and ethnic-specific differences in Bulgarian patients with Wilson disease. Neurologist 18: 104–109.
41. Holder H, Willems-Polfi C, Knolpill C, Gabriel G, Vogel W, et al. (2012) Identification of a novel Wilson disease gene mutation frequent in Upper Austria: a genetic and clinical study. J Hum Genet 57: 364–367.
42. Deguti MM, Genschel J, Cancado EL, Barbosa ER, Bochow B, et al. (2004) Wilson disease: novel mutations in the ATP7B gene and clinical correlation in Brazilian patients. Hum Mutat 23: 398.
43. Simsek Papur O, Akman SA, Calmuk R, Terzioglu O (2013) Mutation analysis of ATP7B gene in Turkish Wilson disease patients: identification of five novel mutations. Eur J Med Genet 56: 175–179.
44. Keandaungjuntr J, Busabaratana M, Keotsichaiw C, Sura T, Pakels T (2011) Analysis of exon 8 of ATP7B gene in Thai patients with Wilson disease. J Med Assoc Thai 94: 1184–1188.